Radiotherapy is one of the cornerstones of modern cancer treatment. In recent years and decades, innovations have been made primarily in the fields of physics and technology, such as image-guided radiotherapy (IGRT), various new entities of radiation or magnetic resonance-guided radiotherapy (SMART). Despite these advances, the prognoses of many cancers are still poor at present. Very often, the effectiveness of radiotherapeutic interventions is limited by the sometimes high degree of tumor-intrinsic resistance to the effects of radiation, given by the damage to genomic DNA. Our research group therefore conducts translational research in close collaboration with the clinic in order to identify new biomarkers for the response of tumors to radiotherapy and thus new possibilities for targeted interventions as additions to the currently clinically used treatment regimens.
Molecular Radiation Oncology
Current research projects:
- Investigation of targeted treatment approaches with regard to their potential to sensitize glioblastoma to radiotherapy and radiochemotherapy.
- Functional investigation of candidate genes with biomarker potential for response to radiochemotherapy in rectal cancer.
- Functional investigation / validation of candidate genes for different radiochemotherapy regimes in esophageal cancer.
Methods:
- Generation of OMICs data from patient material in the course of clinical studies.
- Correlation of corresponding OMICs data with clinical parameters.
- Functional validation of candidates (preclinical and clinical).
Leitung
Forschungsgruppenleiter
Phone number: +49 7071 29-82183
E-mail address: michael.orth@med.uni-tuebingen.de
Publications: Publikationen
Certificates and Associations
Focus: Top Nationales Krankenhaus 2024
Qualitätspartnerschaft mit der PKV
Erfolgsfaktor Familie
Die Altersvorsorge für den Öffentlichen Dienst